A Case of Development of Vitiligo Followed by TNF-alpha Antagonist Treatment for Rheumatoid Arthritis
Journal of Rheumatic Diseases
; : 216-219, 2012.
Article
in Ko
| WPRIM
| ID: wpr-11342
Responsible library:
WPRO
ABSTRACT
As the usage of biologics for rheumatic diseases increases, such as rheumatoid arthritis and ankylosing spondylitis, various cutaneous adverse events are also being increasingly reported. We experienced a case of development of vitiligo during a TNF-alpha antagonist therapy in a 22-year-old woman with rheumatoid arthritis. The patient was presented with vitiligo lesions on the dorsum of both hands after 1 month of treatment with etanercept. Vitiligo improved with topical tacrolimus ointment and excimer laser treatment without the discontinuation of etanercept. No clearly defined mechanism for vitiligo induced by TNF-alpha antagonist exits. However, considering that vitiligo is an autoimmune disorder, the development of this skin lesion in association with the TNF-alpha antagonist could be explained by a paradoxical induction of the autoimmune process.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Arthritis, Rheumatoid
/
Skin
/
Spondylitis, Ankylosing
/
Vitiligo
/
Immunoglobulin G
/
Rheumatic Diseases
/
Tumor Necrosis Factor-alpha
/
Tacrolimus
/
Receptors, Tumor Necrosis Factor
/
Lasers, Excimer
Limits:
Female
/
Humans
Language:
Ko
Journal:
Journal of Rheumatic Diseases
Year:
2012
Type:
Article